Physiological and pharmacological roles of FGF21 in cardiovascular diseases

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Cheng, Peng ^a   Zhang, Fangfang ^a   Yu, Lechu ^a   Lin, Xiufei ^a   He, Luqing ^a   Li, Xiaokun ^a   Lu, Xuemian ^a   Yan, Xiaoqing ^a   Tan, Yi ^a,b   Zhang, Chi ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; REVIEW; THERAPY EFFECT; ANIMAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETIC CARDIOMYOPATHIES; FIBROBLAST GROWTH FACTORS; HUMANS; OXIDATIVE STRESS;

EID: 84973336072     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1540267     Document Type: Review

References (87)

1. Y. Yang, W. Duan, Y. Li, et al., "Novel role of silent information regulator 1 inmyocardial ischemia, " Circulation, vol. 128, no. 20, pp. 2232-2240, 2013.
2. C. D. Mathers and D. Loncar, "Projections of global mortality and burden of disease from 2002 to 2030, " PLoS Medicine, vol. 3, no. 11, pp. 2011-2030, 2006.
3. W. H. Burgess and T. Maciag, "The heparin-binding (fibroblast) growth factor family of proteins, " Annual Review of Biochemistry, vol. 58, pp. 575-606, 1989.
4. D. B. Rifkin and D. Moscatelli, "Recent developments in the cell biology of basic fibroblast growth factor, " The Journal of Cell Biology, vol. 109, no. 1, pp. 1-6, 1989.
5. T. P. Yamaguchi and J. Rossant, "Fibroblast growth factors in mammalian development, " Current Opinion in Genetics & Development, vol. 5, no. 4, pp. 485-491, 1995.
6. F. Guillemot and C. Zimmer, "Fromcradle to grave: themultiple roles of fibroblast growth factors in neural development, " Neuron, vol. 71, no. 4, pp. 574-588, 2011.
7. M. Goldfarb, "Fibroblast growth factor homologous factors: evolution, structure, and function, " Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 215-220, 2005.
8. K. H. Bae, J. G. Kim, and K. G. Park, "Transcriptional regulation of fibroblast growth factor 21 expression, " Endocrinology and Metabolism, vol. 29, no. 2, pp. 105-111, 2014.
9. N. Itoh and D. M. Ornitz, "Evolution of the Fgf and Fgfr gene families, " Trends in Genetics, vol. 20, no. 11, pp. 563-569, 2004.
10. W. L. McKeehan, F. Wang, and M. Kan, "The heparan sulfatefibroblast growth factor family: diversity of structure and function, " Progress in Nucleic Acid Research and Molecular Biology, vol. 59, pp. 135-176, 1998.
11. T. Nishimura, Y. Nakatake, M. Konishi, and N. Itoh, "Identification of a novel FGF, FGF-21, preferentially expressed in the liver, " Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, vol. 1492, no. 1, pp. 203-206, 2000.
12. T. Inagaki, P. Dutchak, G. Zhao, et al., "Endocrine regulation of the fasting response by PPARγ-mediated induction of fibroblast growth factor 21, " Cell Metabolism, vol. 5, no. 6, pp. 415-425, 2007.
13. E. S. Muise, B. Azzolina, D. W. Kuo, et al., "Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferatoractivated receptor γ and altered metabolic states, " Molecular Pharmacology, vol. 74, no. 2, pp. 403-412, 2008.
14. H. Wang, L. Qiang, and S. R. Farmer, "Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes, " Molecular and Cellular Biology, vol. 28, no. 1, pp. 188-200, 2008.
15. H. Kurosu, M. Choi, Y. Ogawa, et al., "Tissue-specific expression of klotho and Fibroblast Growth Factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21, " The Journal of Biological Chemistry, vol. 282, no. 37, pp. 26687-26695, 2007.
16. A. Kharitonenkov, T. L. Shiyanova, A. Koester, et al., "FGF-21 as a novel metabolic regulator, "The Journal of Clinical Investigation, vol. 115, no. 6, pp. 1627-1635, 2005.
17. A. Kharitonenkov, J. D. Dunbar, H. A. Bina, et al., "FGF-21/FGF-21 receptor interaction and activation is determined by Klotho, " Journal of Cellular Physiology, vol. 215, no. 1, pp. 1-7, 2008.
18. J. Xu, S. Stanislaus, N. Chinookoswong, et al., "Acute glucoselowering and insulin-sensitizing action of FGF21 in insulinresistant mouse models-association with liver and adipose tissue effects, " American Journal of Physiology-Endocrinology and Metabolism, vol. 297, no. 5, pp. E1105-E1114, 2009.
19. J. Yie, W. Wang, L. Deng, et al., "Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling, " Chemical Biology and Drug Design, vol. 79, no. 4, pp. 398-410, 2012.
20. A. Kharitonenkov and A. C. Adams, "Inventing newmedicines: the FGF21 story, " Molecular Metabolism, vol. 3, no. 3, pp. 221-229, 2014.
21. M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, et al., " Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c, " Molecular Endocrinology, vol. 22, no. 4, pp. 1006-1014, 2008.
22. I. Urakawa, Y. Yamazaki, T. Shimada, et al., "Klotho converts canonical FGF receptor into a specific receptor for FGF23, " Nature, vol. 444, no. 7120, pp. 770-774, 2006.
23. H. Li, J. Zhang, and W. Jia, "Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology, " Frontiers of Medicine, vol. 7, no. 1, pp. 25-30, 2013.
24. S. A. Kliewer and D. J. Mangelsdorf, "Fibroblast growth factor 21: from pharmacology to physiology, " The American Journal of Clinical Nutrition, vol. 91, no. 1, pp. 254S-257S, 2010.
25. T. Kotulak, J. Drapalova, P. Kopecky, et al., "Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance, " Physiological Research/Academia Scientiarum Bohemoslovaca, vol. 60, pp. 757-767, 2011.
26. K. I. Stanford, R. J. W. Middelbeek, K. L. Townsend, et al., "Brown adipose tissue regulates glucose homeostasis and insulin sensitivity, "The Journal of Clinical Investigation, vol. 123, no. 1, pp. 215-223, 2013.
27. F. G. Schaap, A. E. Kremer, W. H. Lamers, P. L. M. Jansen, and I. C. Gaemers, "Fibroblast growth factor 21 is induced by endoplasmic reticulumstress, " Biochimie, vol. 95, no. 4, pp. 692-699, 2013.
28. X. Zhang, D. C. Y. Yeung, M. Karpisek, et al., "Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans, " Diabetes, vol. 57, no. 5, pp. 1246-1253, 2008.
29. Y. Xiao, L. Liu, A. Xu, et al., "Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes, " Cardiovascular Diabetology, vol. 14, article 72, 2015.
30. C. Zhang, Z. Huang, J. Gu, et al., "Fibroblast growth factor 21 protects the heart from apoptosis in a diabeticmousemodel via extracellular signal-regulated kinase 1/2-dependent signalling pathway, " Diabetologia, vol. 58, no. 8, pp. 1937-1948, 2015.
31. A. J. Lusis, "Atherosclerosis, " Nature, vol. 407, no. 6801, pp. 233-241, 2000.
32. J. Davignon, "Advances in lipid-lowering therapy in atherosclerosis, " Advances in ExperimentalMedicine and Biology, vol. 498, pp. 49-58, 2001.
33. Z. Lin, Z. Wu, X. Yin, et al., "Serumlevels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile, " PLoS ONE, vol. 5, no. 12, Article ID e15534, 2010.
34. W. S. Chow, A. Xu, Y. C. Woo, et al., "Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 10, pp. 2454-2459, 2013.
35. Z. Lin, X. Pan, F. Wu, et al., "Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice, " Circulation, vol. 131, no. 21, pp. 1861-1871, 2015.
36. X. Wu, Y. Lyu, K. Fu, et al., "Impact of exogenous fibroblast growth factor 21 on atherosclerosis in apolipoprotein E deficient mice, " Zhonghua Xin Xue Guan Bing Za Zhi, vol. 42, no. 2, pp. 126-131, 2014.
37. X. Wu, Y.-F. Qi, J.-R. Chang, et al., "Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE-/-mice, " Heart and Vessels, vol. 30, no. 5, pp. 657-668, 2015.
38. W. Zhu, C. Wang, L. Liuet al., "Effects of fibroblastgrowthfactor on cell damage in vitro and atherosclerosis in vivo, " Canadian Journal of Physiology and Pharmacology, vol. 92, no. 11, pp. 927-935, 2014.
39. S. K. Bhatia, "Tissue engineering for clinical applications, " Biotechnology Journal, vol. 5, no. 12, pp. 1309-1323, 2010.
40. D. P. Faxon, M. A. Creager, S. C. Smith Jr., et al., "Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association, " Circulation, vol. 109, no. 21, pp. 2595-2604, 2004.
41. B. Akadam-Teker, O. Kurnaz, E. Coskunpinar, et al., "Theeffects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease, " Gene, vol. 528, no. 2, pp. 93-98, 2013.
42. P. Rajendran, T. Rengarajan, J. Thangavel, et al., "The vascular endothelium and human diseases, " International Journal of Biological Sciences, vol. 9, no. 10, pp. 1057-1069, 2013.
43. J. Galle, T. Hansen-Hagge, C. Wanner, and S. Seibold, "Impactof oxidized low density lipoprotein on vascular cells, " Atherosclerosis, vol. 185, no. 2, pp. 219-226, 2006.
44. M. T. Quinn, S. Parthasarathy, and D. Steinberg, "Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 8, pp. 2805-2809, 1988.
45. J. Frostegard, A. Haegerstrand, M. Gidlund, and J. Nilsson, "Biologically modified LDL increases the adhesive properties of endothelial cells, " Atherosclerosis, vol. 90, no. 2-3, pp. 119-126, 1991.
46. S. Yui, T. Sasaki, A. Miyazaki, S. Horiuchi, and M. Yamazaki, "Induction of murine macrophage growth by modified LDLs, " Arteriosclerosis andThrombosis, vol. 13, no. 3, pp. 331-337, 1993.
47. V. Lindner, D. A. Lappi, A. Baird, R. A. Majack, and M. A. Reidy, "Role of basic fibroblast growth factor in vascular lesion formation, " Circulation Research, vol. 68, no. 1, pp. 106-113, 1991.
48. S. Jimi, K. Saku, N. Uesugi, N. Sakata, and S. Takebayashi, "Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells, " Atherosclerosis, vol. 116, no. 1, pp. 15-26, 1995.
49. A. Loidl, R. Claus, E. Ingolic, H.-P. Deigner, and A. Hermetter, "Role of ceramide in activation of stress-associated MAP kinases by minimally modified LDL in vascular smoothmuscle cells, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1690, no. 2, pp. 150-158, 2004.
50. M. Sata and K. Walsh, "Oxidized LDL activates fas-mediated endothelial cell apoptosis, "The Journal of Clinical Investigation, vol. 102, no. 9, pp. 1682-1689, 1998.
51. S. J. Hardwick, L. Hegyi, K. Clare, et al., "Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein, " The Journal of Pathology, vol. 179, no. 3, pp. 294-302, 1996.
52. C. J. Schwartz, A. J. Valente, E. A. Sprague, J. L. Kelley, and R. M. Nerem, "The pathogenesis of atherosclerosis: an overview, " Clinical Cardiology, vol. 14, no. 2, pp. I-1-I-16, 1991.
53. L.-X. Li, J.-X. Chen, D.-F. Liao, and L. Yu, "Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro, " Endothelium: Journal of Endothelial Cell Research, vol. 6, no. 1, pp. 1-8, 1998.
54. Y. Lu, J.-H. Liu, L.-K. Zhang, et al., "Fibroblast growth factor as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells, " Chinese Medical Journal, vol. 123, no. 23, pp. 3417-3421, 2010.
55. M. Shao, X. Lu, W. Cong, et al., "Multiple low-dose radiation prevents type 2 diabetes-induced renal damage through attenuation of dyslipidemia and insulin resistance and subsequent renal inflammation and oxidative stress, " PLoS ONE, vol. 9, no. 3, Article ID e92574, 2014.
56. Y. Shen, X. Ma, J. Zhou, et al., "Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease, " Cardiovascular Diabetology, vol. 12, article124, 2013.
57. W. J. Kim, S. S. Kim, H. C. Lee, et al., "Association between serumfibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes, " Journal of Koreanmedical science, vol. 30, no. 5, pp. 586-590, 2015.
58. Y. Lee, S. Lim, E.-S. Hong, et al., "Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status, " Clinical Endocrinology, vol. 80, no. 1, pp. 57-64, 2014.
59. S. Q. Liu, D. Roberts, A. Kharitonenkov, et al., "Endocrine protection of ischemicmyocardiumby FGF21 fromthe liver and adipose tissue, " Scientific Reports, vol. 3, article 2767, 2013.
60. S. Q. Liu, B. J. Tefft, D. T. Roberts, et al., "Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 12, pp. H1446-H1458, 2012.
61. V. Patel, R. Adya, J. Chen, et al., "Novel insights into the cardioprotective effects of FGF21 in lean and obese rat hearts, " PLoS ONE, vol. 9, no. 2, Article ID e87102, 2014.
62. W.-T. Cong, J. Ling, H.-S. Tian, et al., "Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury, " Canadian Journal of Physiology and Pharmacology, vol. 91, no. 11, pp. 973-984, 2013.
63. Z. Lin, X. Pan, F. Wu, et al., "Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice, " Circulation, vol. 131, no. 21, pp. 1861-1871, 2015.
64. A. Planavila, I. Redondo, E. Hondares, et al., "Fibroblast growth factor 21 protects against cardiac hypertrophy in mice, " Nature Communications, vol. 4, article 2019, 2013.
65. A. Planavila, I. Redondo-Angulo, F. Ribas, et al., "Fibroblast growth factor 21 protects the heart from oxidative stress, " Cardiovascular Research, vol. 106, no. 1, pp. 19-31, 2015.
66. X. Yan, J. Chen, C. Zhang, et al., "FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation, " Journal of Cellular andMolecularMedicine, vol. 19, no. 7, pp. 1557-1568, 2015.
67. W. Nadruz, "Myocardial remodeling in hypertension, " Journal of Human Hypertension, vol. 29, no. 1, pp. 1-6, 2015.
68. S. Yamamoto, S. Kita, T. Iyoda, T. Yamada, and T. Iwamoto, "New molecular mechanisms for cardiovascular disease: cardiac hypertrophy and cell-volume regulation, " Journal of Pharmacological Sciences, vol. 116, no. 4, pp. 343-349, 2011.
69. S. P. Barry, S. M. Davidson, and P. A. Townsend, "Molecular regulation of cardiac hypertrophy, "The International Journal of Biochemistry&Cell Biology, vol. 40, no. 10, pp. 2023-2039, 2008.
70. L. T. Shenje, P. Andersen, M. K. Halushka, et al., "Mutations in Alstrom protein impair terminal differentiation of cardiomyocytes, " Nature Communications, vol. 5, article 3416, 2014.
71. J. Lovric, M. Mano, L. Zentilin, A. Eulalio, S. Zacchigna, and M. Giacca, "Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins, " MolecularTherapy, vol. 20, no. 11, pp. 2087-2097, 2012.
72. E. D. Frohlich and D. Susic, "Pressure overload, " Heart Failure Clinics, vol. 8, no. 1, pp. 21-32, 2012.
73. D. Grove, R. Zak, K. G. Nair, and V. Aschenbrenner, "Biochemical correlates of cardiac hypertrophy. IV. Observations on the cellular organization of growth during myocardial hypertrophy in the rat, " Circulation Research, vol. 25, no. 4, pp. 473-485, 1969.
74. D. Grove, K. G. Nair, and R. Zak, "Biochemical correlates of cardiac hypertrophy. 3. Changes in DNA content; the relative contributions of polyploidy and mitotic activity, " Circulation Research, vol. 25, no. 4, pp. 463-471, 1969.
75. F. Simko, K. R. Bednarova, K. Krajcirovicova, et al., "Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure, " Journal of Pineal Research, vol. 57, no. 2, pp. 177-184, 2014.
76. P. K. Gupta, D. J. DiPette, and S. C. Supowit, "Protective effect of resveratrol against pressure overload-induced heart failure, " Food Science & Nutrition, vol. 2, no. 3, pp. 218-229, 2014.
77. N. Itoh and H. Ohta, "Pathophysiological roles of FGF signaling in the heart, " Frontiers in Physiology, vol. 4, article 247, 2013.
78. J. R. Sowers, M. Epstein, and E. D. Frohlich, "Diabetes, hypertension, and cardiovascular disease an update, " Hypertension, vol. 37, no. 4, pp. 1053-1059, 2001.
79. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy revisited, " Circulation, vol. 115, no. 25, pp. 3213-3223, 2007.
80. H. Bugger and E. D. Abel, "Molecular mechanisms of diabetic cardiomyopathy, " Diabetologia, vol. 57, no. 4, pp. 660-671, 2014.
81. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy, causes and effects, " Reviews in Endocrine & Metabolic Disorders, vol. 11, no. 1, pp. 31-39, 2010.
82. L. Cai and Y. J. Kang, "Oxidative stress and diabetic cardiomyopathy: a brief review, " Cardiovascular Toxicology, vol. 1, no. 3, pp. 181-193, 2001.
83. E. Acar, D. Ural, U. Bildirici, et al., "Diabetic cardiomyopathy, " The Anatolian Journal of Cardiology, vol. 11, pp. 732-737, 2011.
84. L. Cai and Y. J. Kang, "Cell death and diabetic cardiomyopathy, " Cardiovascular Toxicology, vol. 3, no. 3, pp. 219-228, 2003.
85. E. G. Nabel, "Cardiovascular disease, "The New England Journal of Medicine, vol. 349, no. 1, pp. 60-72, 2003.
86. B. G. Nordestgaard and A. Varbo, "Triglycerides and cardiovascular disease, " The Lancet, vol. 384, no. 9943, pp. 626-635, 2014.
87. J.-L. Chiasson and J. L. Lorier, "Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes, " The Lancet, vol. 384, no. 9958, pp. 1906-1907, 2014.